Moonlake immunotherapeuticsMLTX.US Overview

US StockHealthcare

(No presentation for MLTX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

MLTX Overall Performance

MLTX AI Analysis & Strategy

MLTX Recent Performance

-0.63%

Moonlake immunotherapeutics

0.81%

Avg of Sector

-1.14%

S&P500

MLTX PowerScanner

MLTX Key Information

MLTX Valuation Metrics

MLTX Earnings Table

MLTX Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.